Clare Saunders
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Clare Saunders has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Jane Carolyn Davies
National Heart and Lung Institute, Imperial College London
8 shared publications - Christopher Short
National Heart and Lung Institute Imperial College London London UK
5 shared publications - Rebecca Dobra
National Heart and Lung Institute, Imperial College London, London, UK
3 shared publications - Felix Ratjen
Translational Medicine Program The Hospital for Sick Children Toronto Ontario Canada
2 shared publications Jane C. Davies
National Heart and Lung Institute, Imperial College London, United Kingdom; Royal Brompton Hospital, Guys & St Thomas' NHS Foundation Trust, London, United Kingdom
2 shared publications- Lutz Naehrlich
Department of Pediatrics, Justus-Liebig-University Giessen, Giessen, Germany
2 shared publications
Latest Publications
- Open Access
- 6 December 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 25 (2) , 257-261
Heterogeneous use of multiple breath washout in cystic fibrosis across age groups and European countries: an ECFSPR analysis
- 6 December 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 25 (2) , 257-261
Open AccessHeterogeneous use of multiple breath washout in cystic fibrosis across age groups and European countries: an ECFSPR analysis
- Open Access
- 4 July 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (4) , 669-683
Pulmonary endpoints in clinical trials for children with cystic fibrosis under two years of age
- 4 July 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (4) , 669-683
Open AccessPulmonary endpoints in clinical trials for children with cystic fibrosis under two years of age
- 13 January 2025
- Published by BMJ in Archives of Disease in Childhood - Education & Practice Edition
- Vol. 110 (5) , 214-217
Utility and interpretation of multiple breath washout in children with cystic fibrosis
Transformative changes in the health of children with cystic fibrosis (CF) mean that more sensitive outcome measures are needed to monitor paediatric CF lung disease. Multiple breath washout (MBW) and its primary readout lung clearance index are gaining increasing traction as an endpoint for clinical trials in the CF space and show promise as a clinical investigation. In this article, we use four clinically based questions to explore what MBW can and cannot (yet) do and highlight some of its strengths and weaknesses as an investigation. We end by discussing how we can increase the utility of MBW as an investigation in children with CF.
- 13 January 2025
- Published by BMJ in Archives of Disease in Childhood - Education & Practice Edition
- Vol. 110 (5) , 214-217
Utility and interpretation of multiple breath washout in children with cystic fibrosis
Transformative changes in the health of children with cystic fibrosis (CF) mean that more sensitive outcome measures are needed to monitor paediatric CF lung disease. Multiple breath washout (MBW) and its primary readout lung clearance index are gaining increasing traction as an endpoint for clinical trials in the CF space and show promise as a clinical investigation. In this article, we use four clinically based questions to explore what MBW can and cannot (yet) do and highlight some of its strengths and weaknesses as an investigation. We end by discussing how we can increase the utility of MBW as an investigation in children with CF.
- Open Access
- 4 October 2022
- Published by Wiley in Pediatric Pulmonology
- Vol. 58 (1) , 328-331
Migration is not the perfect answer: How the cross‐talk error correction for multiple breath nitrogen washout (MBWN2) parameters differs on directly collected vs. legacy data
Recently, a cross‐talk error with commercial multiple breath nitrogen washout (MBWN2) software was discovered, which produced an absolute over‐reading of N2 of approximately 1%, i.e., 2% N2 read as 3%. This caused an extended tail to the washout, and over‐estimated lung clearance index (LCI2.5) values. Subsequently an updated and corrected software version has been released. Within the field there have been discussions on how to correct legacy data, whether to migrate or completely “rerun” raw data A‐files from the old software into the new corrected software. To our knowledge, no research has been published assessing whether either method is equivalent to directly collecting data in the new corrected software. We prospectively recruited 19 participants, 10 adult healthy controls and 9 people with cystic fibrosis (CF). MBWN2 was performed using the Exhalyzer® D first on the old 3.1.6 software and next, directly on corrected 3.3.1 software. Multiple breath washout (MBW) data directly collected in 3.3.1 was significantly different from both migrated and rerun data. A total of 7 of the 19 participants (37%; 4 CF) had a relative difference in LCI2.5 > 10% for both migrated and rerun data compared to 3.3.1 collected data. Our findings have implications for the Global Lung Initiative MBW project, which is accepting a combination of directly collected, A‐file reruns and migrated data to establish normative values. Further, caution must be used in clinical practice when comparing corrected legacy data versus 3.3.1 collected data for clinical interpretation. We recommend that a new baseline is collected directly on 3.3.1. before clinical interpretation and decisions are determined when comparing consecutive MBW tests.
- 4 October 2022
- Published by Wiley in Pediatric Pulmonology
- Vol. 58 (1) , 328-331
Open AccessMigration is not the perfect answer: How the cross‐talk error correction for multiple breath nitrogen washout (MBWN2) parameters differs on directly collected vs. legacy data
Recently, a cross‐talk error with commercial multiple breath nitrogen washout (MBWN2) software was discovered, which produced an absolute over‐reading of N2 of approximately 1%, i.e., 2% N2 read as 3%. This caused an extended tail to the washout, and over‐estimated lung clearance index (LCI2.5) values. Subsequently an updated and corrected software version has been released. Within the field there have been discussions on how to correct legacy data, whether to migrate or completely “rerun” raw data A‐files from the old software into the new corrected software. To our knowledge, no research has been published assessing whether either method is equivalent to directly collecting data in the new corrected software. We prospectively recruited 19 participants, 10 adult healthy controls and 9 people with cystic fibrosis (CF). MBWN2 was performed using the Exhalyzer® D first on the old 3.1.6 software and next, directly on corrected 3.3.1 software. Multiple breath washout (MBW) data directly collected in 3.3.1 was significantly different from both migrated and rerun data. A total of 7 of the 19 participants (37%; 4 CF) had a relative difference in LCI2.5 > 10% for both migrated and rerun data compared to 3.3.1 collected data. Our findings have implications for the Global Lung Initiative MBW project, which is accepting a combination of directly collected, A‐file reruns and migrated data to establish normative values. Further, caution must be used in clinical practice when comparing corrected legacy data versus 3.3.1 collected data for clinical interpretation. We recommend that a new baseline is collected directly on 3.3.1. before clinical interpretation and decisions are determined when comparing consecutive MBW tests.
- Open Access
Going the Extra Mile: Why Clinical Research in Cystic Fibrosis Must Include Children
This is an exciting time for research and novel drug development in cystic fibrosis. However, rarely has the adage, “Children are not just little adults” been more relevant. This article is divided into two main sections. In the first, we explore why it is important to involve children in research. We discuss the potential benefits of understanding a disease and its treatment in children, and we highlight that children have the same legal and ethical right to evidence-based therapy as adults. Additionally, we discuss why extrapolation from adults may be inappropriate, for example, medication pharmacokinetics may be different in children, and there may be unpredictable adverse effects. In the second part, we discuss how to involve children and their families in research. We outline the importance and the complexities of selecting appropriate outcome measures, and we discuss the role co-design may have in improving the involvement of children. We highlight the importance of appropriate staffing and resourcing, and we outline some of the common challenges and possible solutions, including practical tips on obtaining consent/assent in children and adolescents. We conclude that it is unethical to simply rely on extrapolation from adult studies because research in young children is challenging and that research should be seen as a normal part of the paediatric therapeutic journey.
Open AccessGoing the Extra Mile: Why Clinical Research in Cystic Fibrosis Must Include Children
This is an exciting time for research and novel drug development in cystic fibrosis. However, rarely has the adage, “Children are not just little adults” been more relevant. This article is divided into two main sections. In the first, we explore why it is important to involve children in research. We discuss the potential benefits of understanding a disease and its treatment in children, and we highlight that children have the same legal and ethical right to evidence-based therapy as adults. Additionally, we discuss why extrapolation from adults may be inappropriate, for example, medication pharmacokinetics may be different in children, and there may be unpredictable adverse effects. In the second part, we discuss how to involve children and their families in research. We outline the importance and the complexities of selecting appropriate outcome measures, and we discuss the role co-design may have in improving the involvement of children. We highlight the importance of appropriate staffing and resourcing, and we outline some of the common challenges and possible solutions, including practical tips on obtaining consent/assent in children and adolescents. We conclude that it is unethical to simply rely on extrapolation from adult studies because research in young children is challenging and that research should be seen as a normal part of the paediatric therapeutic journey.
- 1 May 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 21 (3) , e204-e207
Impact of cross-sensitivity error correction on representative nitrogen-based multiple breath washout data from clinical trials
- 1 May 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 21 (3) , e204-e207
Impact of cross-sensitivity error correction on representative nitrogen-based multiple breath washout data from clinical trials
- Open Access
- 18 February 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 21 (4) , 675-683
A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant
- 18 February 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 21 (4) , 675-683
Open AccessA Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant
- Open Access
- 1 November 2021
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 20 (6) , 1018-1025
Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis
- 1 November 2021
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 20 (6) , 1018-1025
Open AccessRiociguat for the treatment of Phe508del homozygous adults with cystic fibrosis
- 1 November 2021
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 20 (6) , 986-993
Guiding the rational design of patient-centred drug trials in Cystic Fibrosis: A Delphi study
- 1 November 2021
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 20 (6) , 986-993
Guiding the rational design of patient-centred drug trials in Cystic Fibrosis: A Delphi study
- Open Access
- 15 May 2020
- Published by Wiley in Pediatric Pulmonology
- Vol. 55 (8) , 1855-1858
Horses for courses: Learning from functional tests of pulmonary health?
- 15 May 2020
- Published by Wiley in Pediatric Pulmonology
- Vol. 55 (8) , 1855-1858
Open AccessHorses for courses: Learning from functional tests of pulmonary health?